Türkiye's Competition Authority has concluded its investigation into dietary supplement brand Orzaks. The authority ruled that Orzaks obstructed competition by restricting pharmacies' online sales. The company was fined approximately TRY 35,681,375.91 in administrative penalties. The investigation examined Orzaks' commercial relations with pharmacies: alleged purchase obligations imposed on pharmacies, mandatory bundling of certain product groups, and discount policies that allegedly restricted competition.
The probe also examined claims that the presence and visibility of competing products in the pharmacy channel were limited. In that context, the authority analyzed whether the company used discount and incentive mechanisms to steer pharmacies' product selection. With pharmacy retail being a critical distribution channel for dietary supplements, brand-side intervention in competing-product visibility raised classic vertical competition restraint questions.
Alongside the fine, Orzaks announced its commitments: shelf support and meal-voucher support for D vitamins will be discontinued; pharmacies nationwide will be subject to objective differentiation, and any purchase support extended to pharmacies will be governed by objective criteria. Orzaks will add the wording "In product preference, distributors are free to choose any product they want" at the end of product lists in a clear, readable format. Contracts will additionally include "The pharmacy may use its shelves as it sees fit, including making space for and rendering competing products visible".
From a supply chain and procurement perspective, the decision sets a precedent for pharmacy-channel management in Türkiye. Vertical contracts between brands and pharmacies routinely featured shelf support, purchase obligations and meal-voucher incentives; this fine and these commitments are redrawing the limits of those practices. As the supplement category grows — especially in high-frequency SKUs like Vitamin D — brands' pharmacy-contract designs will be reshaped around objective criteria and product-selection freedom. The ruling's reach will extend beyond Orzaks: as a competition-law precedent, it could push contract templates across supplements, OTC pharma and dermo-cosmetics into alignment.
Key Takeaways:
1. Türkiye's Competition Authority fined dietary supplement brand Orzaks roughly TRY 35.68 million for restricting pharmacies' online sales.
2. The probe covered alleged purchase obligations, mandatory bundling and discount policies that restricted rival product visibility.
3. Orzaks commitments: shelf support and meal-voucher support for D vitamins will be discontinued; pharmacies will be differentiated only by objective criteria.
4. Contracts will include 'distributors are free to choose any product they want' and 'pharmacy may use shelves to feature competing products.'
5. The ruling sets a precedent — supplement, OTC pharma and dermo-cosmetics brand-pharmacy contract templates are likely to be redesigned.
[3624208]
